Sinotherapeutics (688247.SS) Osake Kurssi

Sinotherapeutics Inc is a pharmaceutical company based in Shanghai, China, operating within the Health Care sector. The company focuses on the research and development, production, and sales of high-end generic drugs, alongside offering Contract Research Organization (CRO) services. Sinotherapeutics went public with an IPO on August 25, 2022, and currently employs 248 full-time staff. Its primary business activities include the development, manufacturing, and distribution of generic pharmaceutical products, as well as providing CRO services to support drug development processes. The company serves both domestic and international markets, though specific details about its market presence or key products are not provided. Sinotherapeutics is listed on the Shanghai Stock Exchange under the ticker 688247.SS and holds the ISIN CNE100005PL9. The company's official website is https://www.sinotherapeutics.com/. It operates as a domestic entity with a focus on pharmaceutical innovation and service delivery within the healthcare industry. No additional details regarding acquisitions, founding year, specific product names, or financial figures are available from the provided information.